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Adipose tissue development and function are widely studied to examine the relationship between obesity and the metabolic
syndrome. It is well documented that the inability of adipose tissue to properly increase its lipid storage capacity during the obese
state can lead to metabolic dysfunction. In a blind screen of 425 botanicals, we identified naringenin as an inhibitor of adipocyte
differentiation. Naringenin is one of the most abundant citrus flavonoids, and recent studies have demonstrated antihyperlipidemic
capabilities. These studies have largely focused on the effects of naringenin on the liver. Our biochemical studies clearly demonstrate
that naringenin inhibits adipogenesis and impairs mature fat cell function. Naringenin specifically inhibited adipogenesis in a dosedependent fashion as judged by examining lipid accumulation and induction of adipocyte marker protein expression. In mature
3T3-L1 adipocytes, naringenin reduced the ability of insulin to induce IRS-1 tyrosine phosphorylation and substantially inhibited
insulin-stimulated glucose uptake in a dose-dependent manner and over a time frame of 1.5 to 24 hours. Exposure to naringenin
also inhibited adiponectin protein expression in mature murine and human adipocytes. Our studies have revealed that naringenin
may have a negative impact on adipocyte-related diseases by limiting differentiation of preadipocytes, by significantly inducing
insulin resistance, and by decreasing adiponectin expression in mature fat cells.

1. Introduction
Adipocytes, once thought to be passive sites of lipid storage,
are now recognized as dynamic insulin-sensitive cells with
endocrine properties that contribute to whole-body energy
homeostasis. Obesity, the primary disease of fat cells, is a
major risk factor of metabolic syndrome and significantly
contributes to the development of type 2 diabetes mellitus (T2DM), cardiovascular disease, and certain cancers
(reviewed in [1, 2]). Limiting the development of adipose
tissue was once considered a good way to combat obesity. In
fact, many researchers investigated antiadipogenic agents as
potential therapeutics for decreasing or preventing obesity.
However, the prevailing current hypothesis is that disruption
of adipocyte differentiation limits adipose tissue expansion,

which is linked to insulin resistance and the development of
T2DM [3–5].
In the United States and worldwide, awareness of the
economic burden and health consequences associated with
the growing obesity epidemic is rising [6]. This increased
awareness, accompanied by dissatisfaction with conventional
pharmaceuticals in dealing with chronic conditions, such
as obesity and metabolic syndrome, has prompted interest
among researchers and the general public in herbal or
botanical remedies to treat these conditions [7]. However,
often the safety and mechanism of action of the individual
bioactive constituents are not well defined.
Our laboratory participated in a blinded screening study
to investigate the ability of over 400 botanicals to modulate
adipocyte differentiation. Although less than 2% of the
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plant extracts or pure phytochemicals in our screen had
substantial effects on adipogenesis, we identified naringenin
to be antiadipogenic.
Naringenin is an abundant aglycone flavanone found
in grapefruit and other citrus fruits, and it has been
recently reported to have anti-hyperlipidemic [8] and antihyperglycemic properties [9]. In contrast to these potential metabolically beneficial effects, our screening studies
revealed that naringenin inhibited adipogenesis, indicating
possible detrimental effects on adipose tissue expansion and
insulin sensitivity. In these studies, we have evaluated the
specific effects of naringenin on adipocyte development.
Additionally, we tested the hypothesis that naringenin would
also have negative effects on insulin sensitivity and adipokine
production in mature mouse and human adipocytes.

2. Materials and Methods
2.1. Materials. Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Sigma-Aldrich (St. Louis, MO,
USA). Bovine and fetal bovine sera were purchased from
HyClone (Thermo Scientific, Logan, UT, USA). Naringenin
was purchased from Sigma-Aldrich and also was provided as
a compound purified from a botanical extract at the Rutgers
Botanical Core facility. For immunoblotting, the polyclonal
STAT5A and MAPK (ERK 1) IgG’s and the PPAR𝛾 monoclonal antibody were purchased from Santa Cruz Biotechnology. The polyclonal anti-aP2 (FABP4) and antiadiponectin
antibodies were purchased, respectively, from Abcam (Cambridge, MA, USA) and Pierce (Thermo Scientific, Rockford, IL, USA). This polyclonal antiadiponectin antibody
is reactive only against murine adiponectin. Therefore, to
probe the whole cell extracts from human adipocytes, we
used a monoclonal antiadiponectin IgG from Thermo Scientific that is reactive against both murine and human
adiponectin. Antiphospho-IRS-1 (Tyr896 ), which is polyclonal
and highly specific for phosphotyrosine 896 of the mouse
IRS-1, was purchased from Invitrogen (Carlsbad, CA, USA).
The BCA and enhanced chemiluminescence kits were from
Pierce. Anti-rabbit and anti-mouse horseradish peroxidaseconjugated secondary antibodies were purchased from Jackson ImmunoResearch Laboratories. Mature human subcutaneous adipocytes were purchased in a 12-well plate format
from Zen-Bio. These mature human adipocytes were derived
from preadipocytes collected from the subcutaneous thigh
region of nondiabetic females with a BMI of less than 25.
2.2. Cell Culture. Murine 3T3-L1 preadipocytes were plated
and grown to 2 days after confluence in DMEM containing 10% bovine serum. Medium was changed every 48–72
hours. Cells were induced to differentiate by changing the
medium to DMEM containing a standard MDI induction
cocktail of 10% fetal bovine serum (FBS), 0.5 mM 3-isobutyl1-methylxanthine, 1 𝜇M dexamethasone, and 1.7 𝜇M insulin.
After 48 h, this medium was replaced with DMEM supplemented with 10% FBS and 0.43 𝜇M insulin. Each additional
feeding occurred every 2-3 days in DMEM supplemented
with 10% FBS, and cells were maintained in this medium
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until utilized for experimentation. Human subcutaneous
adipocytes were maintained in adipocyte maintenance media
(Zen-BIO Cat # AM-1) and used for experimentation within
one week of arrival.
2.3. Whole Cell Extract Preparation. Monolayers of 3T3-L1
adipocyte cells were harvested in a nondenaturing buffer
containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA,
1 mM EDTA, 1% Triton X-100, 0.5% IGEPAL CA-630, 1 𝜇M
phenylmethylsulfonyl fluoride, 1 𝜇M pepstatin, 1 mM 1,10phenanthroline, 50 trypsin inhibitory milliunits of aprotinin,
10 𝜇M leupeptin, and 2 mM sodium vanadate. The samples
were either extracted on ice for 30 min or frozen at −80∘ C.
Following the incubation period or thawing of frozen samples, the samples were centrifuged at 13 000 ×g at 4∘ C for
10 min. Supernatants containing whole cell extracts were
analyzed for protein content using a BCA kit according to the
manufacturer’s instructions.
2.4. Gel Electrophoresis and Immunoblotting. Proteins were
separated on 7.5%, 10%, or 15% polyacrylamide (acrylamide
from National Diagnostics) gels containing SDS according
to Laemmli [10] and transferred to a nitrocellulose membrane in 25 mM Tris, 192 mM glycine, and 20% methanol.
Following transfer, the membrane was blocked in 4% milk
overnight at 4∘ C or for 1.5 h at room temperature and then
immunoblotted. Results were visualized with horseradish
peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence. Densitometric analysis of western blot
band intensities was performed using ImageJ [11].
2.5. Oil Red O Staining. An Oil Red O stock was prepared as
previously described [12]. Cell monolayers were aspirated and
rinsed with PBS. Following incubation in a fixative solution
(10% formaldehyde in PBS) for 10–15 min, the monolayers
were rinsed 5 times under tap water. The remaining water
was aspirated, and the cells were incubated for 1 h in the
working Oil Red O solution (0.3% in isopropanol). Following
incubation, the stain was aspirated, the cells were rinsed 5
times under tap water, and then they were examined by eye
and microscopy. For all treatment conditions, the monolayer
was monitored by microscopy and not substantially disturbed
as a result of the staining and aspiration procedure.
2.6. Insulin Stimulated 2-[3 H] Deoxyglucose Uptake Assay.
The assay of 2-[3 H] deoxyglucose uptake was performed as
previously described [13]. Prior to the assay, mature 3T3-L1
adipocytes were serum-deprived for 24 h and pretreated with
naringenin for various times. Next, the cells were incubated in
the presence or absence of insulin (5 nM) for 7 min. Glucose
uptake was initiated by addition of 2-[3 H] deoxyglucose at
a concentration of 0.1 mM 2-deoxyglucose in 1 mCi 2-[3 H]
deoxyglucose in Krebs-Ringer-Hepes buffer and incubated
for 3 min at room temperature. Glucose uptake is reported
as [3 H] radioactivity, normalized to total protein content
as determined by BCA analysis. Nonspecific uptake and
absorption were always less than 10% of the total uptake.
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Uptake measurements were performed in triplicate under
conditions where hexose uptake was linear.
2.7. Statistical Methods. All statistical analyses were performed using the statistical software SAS 9.3 (SAS Institute, Inc., Cary, NC, USA). Each experiment was conducted as a completely randomized design using a factorial
arrangement of interventions, and separate analyses were
performed accordingly. The general linear models procedure
was employed to conduct an analysis of variance for glucose
uptake with insulin at (i) 4 concentrations of naringenin
and (ii) 4 treatment lengths with a control for each level
of factors (i) and (ii). Results were summarized as least
squares means and standard deviations. As expected, the
differences in glucose uptake with and without insulin varied significantly across both factors, necessitating post hoc
pairwise comparisons to characterize the specific findings.
The resulting 𝑃 values were conservatively adjusted using the
method of Scheffé to control the global significance level at
0.05 for each experiment. Thus, statistical significance was
declared for comparisons with adjusted 𝑃 values ≤ 0.05.

3. Results
3.1. Naringenin Inhibits Adipogenesis of 3T3-L1 Cells. We
performed a blinded screen of 425 botanical extracts or
phytochemicals for their ability to modulate adipocyte differentiation of 3T3-L1 cells. We observed that less than 2% of the
extracts had substantial effects on adipocyte differentiation.
One of the botanicals we screened that inhibited adipogenesis
was naringenin. As shown in Figure 1(a), naringenin resulted
in a dose-dependent inhibition of adipogenesis of 3T3-L1 cells
as judged by lipid accumulation. There was no detectable difference in Oil Red O (ORO) staining between control (C) and
DMSO vehicle- (V-) treated cells. Following ORO staining,
we assessed each well using phase contrast microscopy and
ensured that the integrity of the monolayer was not substantially disturbed. When 3T3-L1 preadipocytes were exposed
to the differentiation cocktail and 50 𝜇g/mL naringenin, the
cells maintained a fibroblastic appearance (data not shown)
and did not accumulate lipid (Figure 1(a)). Although the
25 𝜇g/mL dose resulted in a substantial inhibition of lipid
accumulation, there was no notable effect on Oil Red O
staining at the lowest naringenin dose (6 𝜇g/mL) compared
to control and vehicle-treated cells. When the cells were
exposed to naringenin, we did not observe cytotoxic effects
as monitored by microscopic visualization of monolayer
integrity (data not shown). This is in agreement with a
previous study [14] that used lactate dehydrogenase release
to monitor the effect of naringenin and other flavonoids on
the viability of postconfluent, differentiating 3T3-L1 cells.
Adipogenesis was also assessed by examining the induction of adipocyte marker proteins. As shown in Figure 1(b),
the higher doses of naringenin blocked the induction of aP2,
PPAR𝛾, STAT5A, and adiponectin expression that normally
accompanies adipogenesis. The lower doses of naringenin did
not inhibit the induction of these adipocyte markers. Vehicle
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treatment of DMSO had no effect on the expression of adipogenic marker proteins. MAPK expression was measured to
ensure equivalent levels of protein in each sample.
Next, we examined the ability of naringenin to inhibit
differentiation when added at various times after the induction of adipogenesis. As indicated in Figure 1(c), 3T3-L1
preadipocytes were induced to differentiate and naringenin
(25 𝜇g/mL) was added to the induction cocktail at the time of
induction (time 0) and at different time points after induction
of differentiation (24, 48, 72, 96, or 120 hours). At 168 hours
(7 days), whole cell extracts were isolated from the cells in
which naringenin treatment was initiated at the six different
time points, as well as from untreated controls and vehicletreated cells. As shown in Figure 1(c), naringenin effectively
blocked adipogenesis for all treatment periods that began up
to 72 h post-MDI. The effects of naringenin on the expression
of adipocyte marker proteins, with the exception of PPAR𝛾,
were substantially attenuated when treatment began at 96 h
post-MDI, and there were no observable differences in
adipocyte marker protein expression at 120 h (Figure 1(c)).
3.2. Naringenin Decreases Insulin Sensitivity of Mature
Adipocytes. Since naringenin negatively affected adipocyte
development, we hypothesized that it may also impair the
physiology of fully differentiated adipocytes. To assess mature
adipocyte function, we investigated insulin sensitivity (Figures 2 and 3) and adiponectin production (Figure 4). For
the insulin sensitivity studies, we preincubated mature 3T3L1 adipocytes with naringenin or vehicle (indicated as 0 in
Figures 2(a) and 2(b)) and then monitored the uptake of
[H3 ]-labeled 2-deoxyglucose in the presence and absence of
an acute insulin dose. As shown in Figure 2, vehicle-treated
adipocytes were highly responsive to insulin treatment,
which induced a 5-6-fold increase in glucose uptake compared to the basal rate. Although basal rates of glucose uptake
were not significantly altered, overnight preincubation with
naringenin specifically attenuated insulin-stimulated glucose
uptake in a dose-dependent manner (Figure 2(a)). At the
highest concentration tested, naringenin completely blocked
the insulin-induced uptake of glucose into the fat cells,
and at the lowest concentration, it exhibited a minimal but
statistically significant inhibitory effect. We also tested the
ability of naringenin to alter glucose uptake by treating the
adipocytes with 50 𝜇g/mL naringenin for various lengths of
time. As shown in Figure 2(b), naringenin was capable of
considerably inhibiting insulin-stimulated glucose uptake in
mature 3T3-L1 adipocytes with a treatment period as short as
1.5 hours. This inhibitory effect was maintained at 5 and 24
hours. A similar inhibitory response was observed when the
cells were treated with a 25 𝜇g/mL dose of naringenin over the
same time frame—1.5 to 24 hours (data not shown).
To investigate how naringenin disrupts insulin signaling
in fat cells, we examined its ability to inhibit tyrosine
phosphorylation of IRS-1. IRS-1 is a primary substrate of the
insulin receptor. Tyrosine phosphorylation of IRS-1 is crucial
in its ability to transmit insulin’s signal and to activate downstream insulin-responsive pathways, such as the PI3 K/Akt
signaling pathway [15]. Using a phosphospecific anti-IRS-1
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Figure 1: Naringenin blocks differentiation of murine 3T3-L1 preadipocytes. Preadipocytes were induced to differentiate using the typical
MDI induction cocktail. Immediately following induction ((a) and (b)) or at the indicated time point post-MDI (c), cells were treated with
DMSO vehicle (V), the indicated the dose of naringenin ((a) and (b)), or 25 𝜇g/mL naringenin (c). The cells were retreated with the indicated
dose of naringenin following each media change every 48–72 hours as indicated in the methods. The control cells (C) received no treatment.
Each panel is representative of 3–6 independently performed experiments. Oil Red O staining of neutral lipid content was performed 7 days
post-MDI (a). Fifty to one hundred fifty micrograms of protein from whole cell extracts, harvested at four (b) or seven (c) days post-MDI
were subjected to western blot analysis. Band intensities were quantified, normalized against the loading control, MAPK, and presented as a
bar graph next to each immunoblot. Similar dose-dependent patterns of adipocyte marker protein expression were observed when cells were
harvested at either 4 or 7 days post-MDI, and panel (b) contains a representative subset of these blots.
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Figure 2: Naringenin inhibits insulin-sensitive glucose uptake from 1.5 to 24 hours and in a dose-dependent manner. Fully differentiated
3T3-L1 adipocytes were serum-deprived for 24 hours prior to performing glucose uptake assays. Cells were stimulated with 5 nM insulin for 7
minutes. Glucose uptake was initiated by the addition of 2-[3 H] deoxyglucose. The glucose uptake values shown represent the mean ± SEM of
triplicate determinations from three independent experiments. Cells were pretreated with vehicle (DMSO) or the indicated dose of naringenin
overnight (a). Prior to insulin administration, the serum-deprivation medium was refreshed and the cells were retreated with the vehicle and
indicated dose of naringenin. Cells were treated with vehicle (0 time point) for 24 hours or 50 𝜇g/mL of naringenin for the indicated length
of time prior to insulin administration (b). White bars: minus insulin; black bars: plus insulin. Glucose uptake was significantly greater with
insulin (relative to basal uptake): ∗ 𝑃 = 0.002, ∗∗ 𝑃 = 0.0002, and ∗∗∗ 𝑃 < 0.0001. Statistically significant relationships among insulin-stimulated
glucose uptake values are indicated in (a) for all combinations of naringenin doses. # Represents statistical significance (𝑃 < 0.0001) for each
naringenin versus 0 time point. All other comparisons were not statistically significant.
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Figure 3: Naringenin modulates insulin action via attenuation of IRS-1 tyrosine896 phosphorylation. Mature 3T3-L1 adipocytes were serum
deprived overnight and then pretreated with vehicle or 25 𝜇g/mL naringenin (Nar) for 2 hours. The control (C) cells were untreated.
As indicated, cells were then stimulated with 10 nM insulin for 2 minutes prior to preparation of whole cell extracts. One hundred fifty
micrograms of protein from the whole cell extracts were separated by SDS-PAGE, transferred to nitrocellulose, and probed for IRS-1
tyrosine896 phosphorylation using a phosphospecific antibody directed against this site (a). Band intensities were quantified, normalized
against the loading control, MAPK, and presented as a bar graph (b). This experiment was independently repeated three times.
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Figure 4: Naringenin inhibits adiponectin expression in mature 3T3-L1 and subcutaneous human adipocytes. Mature 3T3-L1 adipocytes
cultured in 6 well plates were treated with 50 𝜇g/mL naringenin (Nar) or DMSO vehicle control (C) for the indicated length of time prior to
the preparation of whole cell extracts (a). For each time point, data from two individual wells are shown. Subcutaneous human adipocytes
cultured in 12 well plates were treated with 25 𝜇g/mL naringenin (Nar) for 72 hours prior to harvesting (b). The control cells (C) received
no treatment. For the 48- and 72-hour treatments, cells were treated daily, and the medium was replaced 24 hours prior to harvesting the
whole cell extracts. Fifty to one hundred fifty micrograms of protein from whole cell extracts were separated by SDS-PAGE, transferred to
nitrocellulose, and used for western blot analysis. The anti-mouse adiponectin antibody was used to probe the samples in (a), whereas the
anti-mouse/human adiponectin antibody was use to probe the samples in (b). Band intensities were quantified, normalized against the loading
control, MAPK, and presented as fold change relative to 24 h control (a) or control (b) in a bar graph beneath each immunoblot. Values for
duplicate samples were averaged, and data are presented as mean ± SEM.

pY896 antibody, we monitored the effect of naringenin on
IRS-1 pY896 in mature 3T3-L1 adipocytes following acute
administration of insulin. As shown in Figure 3, we observed
a robust increase in phosphorylation of IRS-1 at Tyr896 following insulin stimulation of untreated control cells. Although
the insulin response of the vehicle-treated cells was similar
to that of the untreated cells, a 2 h naringenin pretreatment
resulted in a significantly lower level of insulin-induced IRS1 tyrosine phosphorylation. In fact, the amount of activated
IRS-1 in the insulin-stimulated, naringenin-treated cells was
comparable to that of the basal levels observed in the control
and vehicle-treated fat cells. In Figure 3, naringenin had a
modest effect on the amount of un-stimulated, basal IRS1 tyrosine phosphorylation relative to control and vehicle
treatments. However, this decrease was not consistently
observed, and nonetheless, naringenin reduced the relative
phosphoactivation IRS-1 (insulin-stimulated versus basal)

from 4.4-fold in vehicle-treated cells to 1.9-fold. MAPK
expression was not altered by acute insulin stimulation and
was examined as a loading control for this experiment.
Similar to its effect on insulin-stimulated glucose uptake,
naringenin also acutely inhibited IRS-1 phosphorylation at 1
hour, and this response was maintained over a 24-hour period
(data not shown). We consistently observed that human
adipocytes were generally less insulin-sensitive than the 3T3L1 fat cells. Nonetheless, we found that naringenin also
attenuated Akt Ser473 phosphorylation in human adipocytes
(data not shown).

3.3. Naringenin Attenuates Adiponectin Expression in 3T3L1 and Human Adipocytes. Decreased expression and/or
secretion of adiponectin, an adipocyte-specific hormone,
strongly correlates with whole-body insulin resistance [16].
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Thus, we examined the ability of naringenin to modulate
adiponectin expression in mature 3T3-L1 adipocytes. As
shown in Figure 4(a), 3T3-L1 adipocytes treated with vehicle
for 48 hours exhibited slightly higher adiponectin expression
than those treated for 24 hours. At the 24-hour time point,
naringenin did not affect adiponectin expression relative
to vehicle-treated fat cells. However, at 48 hours, naringenin substantially inhibited the time-dependent increase
in adiponectin protein expression observed under vehicle
conditions. Duplicate samples at each time point for the
vehicle and naringenin treated cells are shown. We also
monitored the effect of naringenin on adiponectin expression in subcutaneous human adipocytes. Human adipocytes
were untreated or treated with 25 𝜇g/mL naringenin for 72
hours, and then the whole cell extracts were analyzed for
adiponectin content. As shown in Figure 4(b), naringenin
treatment robustly reduced adiponectin protein levels in
human fat cells. These experiments were performed in duplicate and yielded similar results. For Figures 4(a) and 4(b),
MAPK expression was examined to demonstrate equivalent
protein levels in each sample.

4. Discussion
In a blinded screen to identify novel modulators of adipocyte
differentiation, we observed that naringenin, an abundant
grapefruit flavanone, inhibited adipogenesis. Using 3T3L1 cells as a model system, we demonstrated that naringenin specifically suppressed lipid accumulation and the
induction of adipocyte-specific marker proteins in a dosedependent manner. Subsequent to the administration of
the MDI cocktail, growth-arrested postconfluent 3T3-L1
preadipocytes undergo mitotic clonal expansion (MCE) prior
to the exiting cell cycle and expressing genes that yield the
mature adipocyte phenotype [17–19]. Mitotic clonal expansion plays an essential role in adipogenesis of 3T3-L1 cells
and occurs within 48–72 hours after MDI stimulation [19].
Many reagents that inhibit adipogenesis do so by inhibiting
this proliferative phase. Interestingly, in a previous study
on the ability of flavonoids to modulate proliferation and
adipogenesis of 3T3-L1 cells, it was shown that naringenin
exerted substantial antiproliferative effects during the preconfluent phase, but was unable to modulate MCE and
differentiation of 3T3-L1 preadipocytes [14].
We did not examine the effects of naringenin on proliferating preadipocytes or proliferation during the early stages
of adipogenesis. However, we did monitor the ability of
naringenin to inhibit fat cell development when added at
different time points following the induction of adipogenesis.
Naringenin potently blocked differentiation when administration began any time within the clonal proliferative phase,
the first 3 days following MDI stimulation. Furthermore,
when treatment of the cells began at 4 days post-MDI,
naringenin was able to significantly attenuate adipogenesis,
indicating that it is capable of exerting its inhibitory action
at later stages of the differentiation process occurring after
clonal expansion.
In addition to its ability to block adipogenesis of 3T3L1 preadipocytes, our studies demonstrated that naringenin
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also substantially inhibited insulin-sensitive glucose uptake
in fully differentiated adipocytes. This effect was dose dependent and consistent when fat cells were exposed to naringenin
from 1.5 to 24 hours. Pretreatment of murine fat cells with
50 𝜇g/mL naringenin for 1.5, 5, and 24 hours considerably
reduced insulin-sensitive glucose uptake. Although 12 𝜇g/mL
naringenin resulted in minimal inhibition of adipogenesis,
this dose was capable of significantly attenuating glucose
uptake induced by acute insulin treatment, suggesting that
mature adipocytes are more sensitive than preadipocytes to
the effects of naringenin. Several studies in 3T3-L1 [20, 21]
and human adipocytes [20] support our finding that naringenin impairs insulin-sensitive glucose uptake. Our data are
novel because they indicate that the ability of naringenin to
attenuate insulin sensitivity in mature fat cells is more potent
than its ability to impair adipogenesis or lipid accumulation
in differentiating adipocytes.
In adipocytes and skeletal muscle, insulin-stimulated
glucose uptake is mediated via translocation of GLUT4 to
the plasma membrane from intracellular storage vesicles.
Naringenin inhibits insulin-responsive glucose transport in
3T3-L1 adipocytes both directly via interaction with the
GLUT4 transporter and indirectly via impairment of insulin
signaling processes involved in GLUT4 trafficking [20].
Disruption of the insulin signaling pathway by naringenin
is also supported by data demonstrating that naringenin can
inhibit PI3 K activity and phosphorylation of its downstream
target, Akt [21]. Activation of PI3 K and Akt is crucial for
insulin-responsive glucose uptake [22–27].
To further investigate the effects of naringenin on the
insulin signaling cascade in fat cells, we examined its ability
to modulate IRS-1 phosphorylation at tyrosine896 . IRS-1 is
a key protein upstream of PI3 K and Akt, and inhibition of
its expression or tyrosine phosphorylation is often associated
with insulin resistance [15]. Our studies demonstrated that
naringenin significantly reduced insulin-induced phosphorylation of IRS-1 at tyrosine896 in 3T3-L1 adipocytes. Of note,
a previous investigation reported that the inhibitory effect
of naringenin on insulin signaling in adipocytes was not
mediated by modulation of insulin-sensitive IRS-1 tyrosine
phosphorylation [21]. The observed disparity in the ability
of naringenin to modulate IRS-1 tyrosine phosphorylation
between our study and that of Harmon and Patel is likely
attributed to differences in the specificities of the antibodies
used to detect phosphorylated IRS-1, which contains over 20
potential tyrosine phosphorylation sites [28, 29].
Overall, our results support the hypothesis that naringenin inhibits insulin-sensitive glucose uptake at least partially via its ability to impair insulin signaling. In addition to its ability to attenuate Akt Ser473 phosphorylation, our data demonstrate that naringenin also can act
upstream of Akt and inhibit insulin-sensitive IRS-1 Tyr896
phosphorylation in 3T3-L1 adipocytes. Although skeletal
muscle is proposed to be primarily responsible for glucose
disposal following a meal [30], studies have shown that
adipose-selective disruption of the GLUT4 gene weakens
the insulin response in the other insulin-sensitive tissues
(muscle and liver), suggesting that adipose tissue plays an

8
important role in systemic glucose homeostasis [31]. Thus,
we propose that naringenin may be capable of having a
negative impact on whole-body glucose homeostasis via its
ability to induce insulin resistance in adipocytes. Indeed,
a recent study showed that orally administered naringenin
impaired systemic glucose tolerance in mice and hamsters
possibly via inhibition of hypothalamic insulin signaling [32];
however, insulin-responsiveness in adipose tissue was not
examined.
A previous study measured the plasma concentration
of naringenin in human subjects following consumption of
grapefruit juice to be 6𝜇M (1 𝜇g/mL) [33]. Based on the results
of our study, naringenin did not inhibit adipogenesis at this
concentration (Figure 1(a)), and the ability of naringenin to
block insulin-stimulated glucose uptake in a dose-dependent
manner suggests that naringenin would not substantially
attenuate adipocyte insulin sensitivity following grapefruit
juice consumption. However, several recent studies have
proposed that naringenin might be therapeutically beneficial
for the treatment of metabolic dysfunction associated with
hyperlipidemia and hyperglycemia [8, 9, 34, 35]. Pharmacological levels of naringenin could be much higher than the
levels attained following dietary consumption of naringenincontaining foods. Our data indicate that mature adipocytes
are more sensitive to naringenin than differentiating 3T3L1 cells and warrant further investigation of the effects
of pharmacological doses of naringenin on adipose tissue
in vivo.
One method by which adipocytes can modulate systemic
insulin sensitivity is via their ability to secrete hormones,
like adiponectin. Decreased expression and/or secretion of
adiponectin strongly correlates with whole-body insulin
resistance [16]. We observed that naringenin decreased the
protein expression of adiponectin in mouse and human
adipocytes, suggesting that it may modulate insulin action
in other tissues. Notably, in contrast to our observations,
other studies indicated that naringenin increases adiponectin
gene expression [36, 37] and protein secretion [36]. Although
our results do not correlate with the data from these studies, it is not uncommon for gene and protein expression
levels to differ. Additionally, we do not think that these
inconsistencies in adiponectin expression are due to variation in the source of naringenin. In our experiments, we
used naringenin from two separate sources, the Rutgers
Botanical Center and Sigma-Aldrich. All of the experiments shown in this paper were performed with naringenin that was purchased from Sigma-Aldrich, but similar
experiments with the Rutgers naringenin that was purified
from a botanical extract yielded identical results (data not
shown).
Several studies have shown that naringenin has antidiabetic, anti-hyperlipidemic, and insulin-sensitizing effects
in vivo using rodent models of metabolic dysfunction [8,
9, 34, 35]. These positive in vivo observations potentially
contrast with the results of our current study and other
previously reported in vitro observations [20, 21]. We hypothesize two possible theories to account for these divergences.
First, it is possible that a metabolite of naringenin might
be responsible for the in vivo improvement in metabolic
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parameters. Pharmacokinetic studies of naringenin in rats
and humans have yielded controversial results. Although
one study demonstrated high bioavailability of this flavanone
aglycone in rats [38], other investigations indicated that its
glucuronidated metabolite is well absorbed, but the bioavailability of naringenin is low [39, 40].
Alternatively, naringenin may induce insulin-sensitizing
activity in muscle and liver or anti-inflammatory activity in
adipose tissue that outweighs its potentially negative effects
in isolated adipocytes. These hypotheses are supported by
studies examining the effects of naringenin in myocytes and
hepatocytes in vitro and adipose tissue in vivo. Naringenin
has been shown to increase glucose uptake via an AMPKdependent mechanism [41] and exhibit insulin-like effects
in liver cells via a novel mechanism that results in PI3 K
activation [23]. Moreover, dietary supplementation with
naringenin reduced adipose tissue inflammation in a mouse
model of dyslipidemia and metabolic syndrome [34]. Clearly,
future in vitro and in vivo studies of naringenin and its
metabolites are needed to better understand its mechanism(s)
of action in insulin-sensitive cells and how its specific
actions in various tissues might contribute to systemic effects
in vivo.

5. Concluding Remarks
Taken together, novel findings from our study demonstrate
that naringenin is a potent botanically derived antiadipogenic
factor that also negatively impacts adiponectin protein
expression in mature adipocytes. While the effects of naringenin on adiponectin gene expression and protein secretion
have been previously studied [36, 37], to our knowledge, our
study is the first to show that naringenin inhibits adiponectin
protein expression in fully differentiated adipocytes from
both mouse and human. Grapefruit consumption is associated with many beneficial health effects [42–45]. Although
naringenin is a major component of grapefruit and other
citrus fruits, we are not proposing that grapefruit might be
metabolically harmful. However, our studies do suggest that
isolated naringenin may have a negative impact on adipocyterelated diseases by limiting differentiation of preadipocytes
and by inducing insulin resistance and reducing adiponectin
expression in mature fat cells.
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